ClinicalTrials.gov
public full text
Public Domain
Metformin in Psoriatic Arthritis
Psoriatic arthritis (PsA) is a systemic, inflammatory disease. The chronic inflammation in PsA predisposes patients to the metabolic syndrome (MetS). MetS is associated with systemic inflammation and proinflammatory cytokines. Clinical observations and experimental results argue for an anti-inflammatory and immunosuppressant property of MET.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Effect of Metformin on Patients With Osteoarthritis#321673
- Metformin in Post Chronic Pancreatitis Diabetes Mellitus#123429
- Old Drug, New Science: Metformin and the Future of Pharmaceutics#313918
- Metformin as Added on Therapy in Patients With Ulcerative Colitis#18563
- Metformin Use in Rheumatoid Arthritis#369816
Record · ID 891203
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive